{"id":"NCT00322335","sponsor":"GlaxoSmithKline","briefTitle":"Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC","officialTitle":"Phase III, Open, Multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC Compared to a Booster Dose of Infanrix™ Hexa When Given to 14 Month-old Subjects Primed in Study DTPa-HBV-IPV-097 & Boosted in Study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05","primaryCompletion":"2006-07","completion":"2010-09","firstPosted":"2006-05-05","resultsPosted":"2011-01-14","lastUpdate":"2016-10-20"},"enrollment":230,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Haemophilus Influenzae Type b","Neisseria Meningitidis"],"interventions":[{"type":"BIOLOGICAL","name":"Haemophilus influenzae type b- and meningococcal (vaccine)","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix™ penta","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix™ hexa","otherNames":[]},{"type":"BIOLOGICAL","name":"Engerix-B","otherNames":[]},{"type":"BIOLOGICAL","name":"NeisVac-C™","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix™ IPV/HIB","otherNames":[]},{"type":"BIOLOGICAL","name":"Meningitec™","otherNames":[]}],"arms":[{"label":"Menitorix/Pediarix Group","type":"EXPERIMENTAL"},{"label":"Infanrix hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group","type":"ACTIVE_COMPARATOR"},{"label":"Infanrix hexa/Meningitec Group","type":"ACTIVE_COMPARATOR"}],"summary":"This protocol posting deals with objectives \\& outcome measures of the extension phase at Months 18, 30, 42, 54 and 66 post booster. The objectives \\& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00352963). The objectives \\& outcome measures of the Booster phase/study are presented in a separate protocol posting (NCT number =NCT00323050).\n\nThe purpose of this study is to evaluate the persistence of meningococcal serogroup C and Hib antibodies on a yearly basis for a period of 5.5 years after booster vaccination. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.","primaryOutcome":{"measure":"Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:8","timeFrame":"18, 30, 42, 54 and 66 months after booster dose (day 0)","effectByArm":[{"arm":"Menitorix/Pediarix Group","deltaMin":44,"sd":null},{"arm":"Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group","deltaMin":93,"sd":null},{"arm":"Infanrix Hexa/Meningitec Group","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"31 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":2},"locations":{"siteCount":12,"countries":["Spain"]},"refs":{"pmids":["18536619","22828645"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":58},"commonTop":[]}}